Testing a new drug for certain blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Genetic & congenital clinical trials.
This trial tests a new drug, S241656, alone or with other treatments, for people with specific types of blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have not responded to standard treatments or have come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to care for yourself (ECOG score 0–2) and have a life expectancy of at least 3 months.
- You must have a confirmed diagnosis of AML, MDS/AML, or CMML that has not responded to or has come back after at least one standard treatment.
- Your kidneys and liver must be working well enough (specific lab tests will check this).
- You must not have had certain other cancers or heart problems in the past 2 to 6 months.
- You must not be taking certain heartburn medications (PPIs) or specific supplements at the start of the trial.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests BGB-11417 in people with certain bone-marrow (blood) cancers such as AML, MDS, or MDS/MPN. The goal is to find out how the medicine works and whether it can control the cancer.
This trial tests a new drug called APL-4098, given alone or with another medicine, for people with certain blood cancers (AML or MDS) that have come back or not responded to treatment. The goal is to see if it is safe and works well.
This early-phase study tests PEP07, a drug that blocks a cancer signal pathway (Checkpoint Kinase 1). It aims to see how well it works and how safely it can be given to people with certain advanced relapsed or refractory blood cancers.
This Phase 1 study tests SL-401, given with azacitidine and sometimes venetoclax, to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN). It aims to find a safe dose and see whether the combination can improve blood cancer control.
This trial tests a new drug called AMX-883 for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or not responded to other treatments. It studies the drug alone and combined with another medicine to see if it is safe and effective.
This trial tests a new drug (S243249) for people with acute leukemia that has come back or not responded to treatment. It focuses on those with specific gene changes (KMT2A, NUP98, or NPM1c) and aims to see if the drug is safe and effective.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.